Millennium Management’s Celldex Therapeutics CLDX Stock Holding History

Millennium Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-21,400	Closed	-$727K	–	6011
2024 Q3	$727K	Buy	+21,400	New	+$815K	﹤0.01%	4530
2022 Q3	–	Sell	-116,200	Closed	-$3.13M	–	7103
2022 Q2	$3.13M	Buy	+116,200	New	+$3.37M	﹤0.01%	3249
2014 Q1	–	Sell	-2,333	Closed	-$847K	–	3486
2013 Q4	$847K	Buy	+2,333	New	+$899K	﹤0.01%	2382

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Millennium Management's CLDX Position: Q1 2026 in Review

Millennium Management increased its Celldex Therapeutics (CLDX) stake by 3.4% in Q1 2026, buying an estimated $1.11M and bringing the position to 1,253,532 shares worth $39.8M. The position accounts for 0.02% of the portfolio, ranked #1003.

Millennium Management first reported a position in CLDX in Q2 2013 and has held it in 41 quarters since. The position peaked at $57.7M in Q1 2015. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

Millennium Management held 1,253,532 shares of Celldex Therapeutics worth $39.8M as of Q1 2026.
Millennium Management bought 40,827 Celldex Therapeutics shares in Q1 2026, an estimated $1.11M.
Celldex Therapeutics made up 0.02% of Millennium Management's portfolio in Q1 2026, its #1003 holding.
Millennium Management first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 41 quarters since.
Millennium Management's Celldex Therapeutics position peaked at $57.7M in Q1 2015.
228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.